Tavist-D
Executive Summary
Sandoz submits ANDA suitability petition for product containing 1.34 mg clemastine fumarate and 120 mg pseudoephedrine HCI (extended release) instead of 1.34 mg clemastine and 75 mg phenylpropanolamine contained in the listed anti-allergy product.